REG - Genedrive PLC - NICE to accelerate evaluation of Genedrive test

GenedriveAnnouncement

26/09/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220926:nRSZ5094Aa&default-theme=true

RNS Number : 5094A  Genedrive PLC  26 September 2022

genedrive plc

("genedrive" or the "Company")

 

NICE to accelerate evaluation of the Genedrive® MT-RNR1 Test

New Early Value Assessment Programme identifies technologies more rapidly

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company,
announces that the UK's National Institute for Health and Clinical Excellence
("NICE") has transferred the evaluation of the Genedrive® MT-RNR1 test to a
new Early Value Assessment Programme ("EVA"). EVA is a new review process,
created to drive innovation into the hands of healthcare professionals by
actively drawing in digital products, medical devices and diagnostics that
address national unmet needs.

 

The EVA allows the NICE diagnostics advisory committee to consider the
technology much faster, which will result in a published report in a six month
timeframe instead of the initial 63 weeks (approximately 14 months) via the
Diagnostics Assessment Programme. A provisional schedule has been published by
NICE which indicates the consultation process will occur in February 2023.

 

The Genedrive® MT-RNR1 assay is the world's first rapid point-of-care test to
screen infants in an urgent care setting for a genetic variant that will cause
life-long hearing loss when carriers of the variant are given certain
antibiotics. Those that carry the variant can then be given alternative
treatments following detection of the variant by the Genedrive® test.

 

David Budd, CEO of genedrive plc, said: "We are grateful to NICE for their
engagement and interest in our innovative technology and pleased that the
Genedrive® MT-RNR1 test has been fast tracked via their new EVA programme,
which may allow clinicians and patients to benefit from the test sooner. This
is a testament to our technology and our ability to address this unmet need."

 

For further details please contact:

 

 genedrive plc                                       +44 (0)161 989 0245
 David Budd: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Joint Broker)  +44 (0)20 7418 8900
 James Steel

 finnCap (Joint Broker)                              +44 (0)20 7220 0500
 Geoff Nash / Alice Lane

 Walbrook PR Ltd (Media & Investor Relations)        +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                     (mailto:genedrive@walbrookpr.com)
 Paul McManus / Anna Dunphy                          +44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com
(http://www.genedriveplc.com/) )  genedrive plc is a molecular diagnostics
company developing and commercialising a low cost, rapid, versatile, simple to
use and robust point of need molecular diagnostics platform for the diagnosis
of infectious diseases and for use in patient stratification (genotyping),
pathogen detection and other indications. The Company has assays on the market
for the detection of MT-RNR1, HCV, certain military biological targets, a high
throughput SARS-CoV-2 assay and a point of care test for Covid-19.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESUORVRUUUKUAR